Wall Street is not exactly impressed with the Pfizer-Mylan deal
July 29, 2019 at 12:09 PM EDT
EpiPen-maker Mylan NV is merging with Pfizer Inc.’s off-patent drugs business, and Wall Street is not fully on board.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|